2017
Current biologic therapies (including IL-17) and monitoring guidelines
Strober B, Wald J. Current biologic therapies (including IL-17) and monitoring guidelines. 2017, 233-240. DOI: 10.1201/9781315119298-23.Peer-Reviewed Original ResearchTuberculin skin testLatent tuberculosisBiologic therapyQuantiFERON-TB Gold testPhase 3 clinical trialsCurrent biologic therapiesInitiation of treatmentSeverity Index scoreInterferon-gamma releaseEfficacy of treatmentHuman monoclonal antibodyMembrane-bound TNFPsoriasis AreaAtypical presentationGamma releaseSkin testThorough historyClinical trialsGold testIndex scoreControl populationMonoclonal antibodiesTNFAdverse effectsTuberculosis
2007
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
Lebwohl M, Bagel J, Gelfand J, Gladman D, Gordon K, Hsu S, Kalb R, Kimball A, Korman N, Krueger G, Mease P, Morison W, Paller A, Pariser D, Ritchlin C, Strober B, Van Voorhees A, Weinstein G, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal Of The American Academy Of Dermatology 2007, 58: 94-105. PMID: 17980456, DOI: 10.1016/j.jaad.2007.08.030.Peer-Reviewed Original ResearchConceptsLiver function testsBiologic therapyNational Psoriasis FoundationCD4 countAntinuclear antibodiesFunction testsPlatelet countPhysical examinationVaccination practicesTumor necrosis factor blockersNecrosis factor blockersTuberculin skin testTreatment of psoriasisBlood cell countEvidence-based studiesMedical boardsFactor blockersPsoriatic arthritisSkin testBlood countConsensus conferenceParticular therapyBlood chemistryPatientsLive vaccine